Late-Stage Melanoma Sufferers Have More Treatment Options Thanks To Drug Approval

The Food and Drug Administration is bringing in reinforcements for those who suffer inoperable forms of melanoma. Zelboraf, which was recently approved by the government, joins Yervoy — approved in March — as new drugs that doctors believe will help patients live longer after treatment.

According to a UPI story, the director of the Office of Oncology Drug Products in the FDA’s Center for Drug Evaluation and Research says it’s been a breakthrough year for melanoma treatment:

“This has been an important year for patients with late-stage melanoma. Zelboraf is the second new cancer drug approved that demonstrates an improvement in overall survival.”

The FDA green-lighted Zelboraf in its priority review program, a sped-up six-month review process used to review drugs that potentially make major treatment advances.

Breakthrough melanoma drug approved [UPI]